Cisplatin ototoxicity and the possibly protective effect of alpha-melanocyte stimulating hormone

Citation
Ps. Heijmen et al., Cisplatin ototoxicity and the possibly protective effect of alpha-melanocyte stimulating hormone, HEARING RES, 128(1-2), 1999, pp. 27-39
Citations number
24
Categorie Soggetti
da verificare
Journal title
HEARING RESEARCH
ISSN journal
03785955 → ACNP
Volume
128
Issue
1-2
Year of publication
1999
Pages
27 - 39
Database
ISI
SICI code
0378-5955(199902)128:1-2<27:COATPP>2.0.ZU;2-K
Abstract
It is known that adrenocorticotrophic hormone (ACTH)-derived peptides, the so-called melanocortins, can reduce cisplatin-induced neurotoxicity. Recent ly, our group has found that cisplatin-induced ototoxicity can also be redu ced or prevented by treatment with the synthetic melanocortin-like peptide, ORG 2766 (Hamers et al., 1994; De Groot et al., 1997). The present study w as designed to investigate the possibly ameliorating effects of the physiol ogically more relevant naturally occurring neuropeptide alpha-melanocyte st imulating hormone (alpha-MSH) upon cisplatin ototoxicity and to compare its protective effects to those of ORG 2766. For eight consecutive days guinea pigs were treated with cisplatin at a concentration of either 1.5 mg/kg/da y or 2 mg/kg/day. Animals were co-treated with either alpha-MSH (75 mu g/kg /day), ORG 2766 (75 mu g/kg/day), or a sham injection containing physiologi cal saline. Electrocochleography and hair cell counts were performed. Treat ment with 1.5 mg/kg/day cisplatin resulted in a large variability of the mo rphological and electrophysiological data, a variability that might have ma sked possible effects of ORG 2766 and alpha-MSH. Treatment with 2 mg/kg/day cisplatin caused less variable, severe reductions in the compound action p otentials and cochlear microphonics combined with basal and middle-turn out er hair cell loss in five out of six animals. However, in the alpha-MSH co- treated groups, two out of six animals could be classified as normal, two a nimals as moderately affected and two animals as severely affected. In the ORG 2766 co-treated group we found three animals that were not affected and three animals that were severely affected. We conclude that the protective effects of alpha-MSH and ORG 2766 co-treatment are comparable and that alp ha-MSH might be clinically useful in protecting against cisplatin-induced o totoxicity. (C) 1999 Elsevier Science B.V. All rights reserved.